Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2015 Financial Results on October 29, 2015
Get Alerts SGEN Hot Sheet
Join SI Premium – FREE
BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (NASDAQ: SGEN) announced today that it will report its third quarter 2015 financial results on Thursday, October 29, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:
LIVE access on Thursday, October 29, 2015
1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time
- Telephone 877-876-9176 (domestic) or 785-424-1667 (international); conference ID 967802
- Webcast available at www.seattlegenetics.com in the Investors and News section
REPLAY access
- Telephone replay will be available beginning at approximately 4:30 p.m. PT on Thursday, October 29, 2015, through 5:00 p.m. PT on Monday, November 2, 2015, by calling 888-203-1112 (domestic) or 719-457-0820 (international); conference ID 967802
- Webcast replay will be available on the Seattle Genetics website at www.seattlegenetics.com in the Investors and News section
About Seattle Genetics
Seattle Genetics is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer. Seattle Genetics is leading the field in developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. The company’s lead product, ADCETRIS® (brentuximab vedotin), is a CD30-targeted ADC that, in collaboration with Takeda Pharmaceutical Company Limited, is commercially available in more than 55 countries, including the U.S., Canada, Japan and members of the European Union. Additionally, ADCETRIS is being evaluated broadly in more than 30 ongoing clinical trials in CD30-expressing malignancies. Seattle Genetics is also advancing a robust pipeline of clinical-stage programs, including SGN-CD19A, SGN-CD33A, SGN-LIV1A, SGN-CD70A, ASG-22ME, ASG-15ME and SEA-CD40. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including AbbVie, Agensys (an affiliate of Astellas), Bayer, Genentech, GlaxoSmithKline and Pfizer. More information can be found at www.seattlegenetics.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151008005246/en/
Seattle Genetics, Inc.
Peggy Pinkston, 425-527-4160
[email protected]
Source: Seattle Genetics, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lockheed Martin (LMT) Tops Q1 EPS by 53c, Beats on Revenue; Offers FY24 Guidance
- Zillow Group (ZG) PT Lowered to $53 at BofA Securities
- Invesco Ltd: Form 8.3 - DS Smith PLC Public dealing disclosure
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!